[Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients]

Rev Rhum Mal Osteoartic. 1981 Jul-Sep;48(7-9):535-41.
[Article in French]

Abstract

vitamin compounds to the basic dialytic treatment of renal osteodystrophy is of contestable interest. Because 1) optimum conditions of dialysis without D vitamin addition prevent efficiently the progress of severe gyperparathyroidism and osteomalacia 2) the D vitamin compunds could render the phosphatemia control more difficult thus contributing to aggravate the histologic lesions of hyperparathyroidism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone and Bones / pathology
  • Calcifediol
  • Chronic Kidney Disease-Mineral and Bone Disorder / blood
  • Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy*
  • Chronic Kidney Disease-Mineral and Bone Disorder / pathology
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxycholecalciferols / administration & dosage*
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood
  • Phosphates / blood
  • Renal Dialysis*

Substances

  • Hydroxycholecalciferols
  • Parathyroid Hormone
  • Phosphates
  • Calcifediol
  • alfacalcidol